UH
TEVA icon

Unigestion Holding’s Teva Pharmaceuticals TEVA Stock Holding History

Unigestion Holding’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-23,100
Closed -$362K – 262
2019
Q1 		$362K Hold
23,100
– – 0.01% 232
2018
Q4 		$356K Buy
+23,100
New +$474K 0.01% 281

Other funds holding TEVA

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Berkshire Hathaway
Berkshire Hathaway Omaha, Nebraska $263B AUM 16.68% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Unigestion Holding's TEVA Position: Q2 2019 in Review

Unigestion Holding sold out of Teva Pharmaceuticals (TEVA) in Q2 2019, closing a stake of 23,100 shares — an estimated $362K sold.

Unigestion Holding first reported a position in TEVA in Q4 2018 and held it in 2 quarters. The position peaked at $362K in Q1 2019. 452 funds tracked by Wall St. Rank hold TEVA as of Q2 2019.

  • Unigestion Holding reported no remaining Teva Pharmaceuticals position as of Q2 2019 after selling out during the quarter.
  • Unigestion Holding sold 23,100 Teva Pharmaceuticals shares in Q2 2019, an estimated $362K.
  • Unigestion Holding first reported a position in Teva Pharmaceuticals in Q4 2018 and held it in 2 quarters.
  • Unigestion Holding's Teva Pharmaceuticals position peaked at $362K in Q1 2019.
  • 452 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2019.

Based on Unigestion Holding's 13F filing for Q2 2019, filed 15 Jul 2019.